State of the Therapeutics Landscape: Q2 2025
Discover how Europe’s therapeutics ecosystem accelerated in Q2 2025. Late-stage financings captured a record 55% of venture capital, while Seed and Series A rounds stayed disciplined and milestone-driven. Oncology led the charge, but we’re also seeing surging interest in CNS, cardiovascular and rare-disease platforms. Dive into the full analysis for regional deal volumes, median ticket trends and the marquee Series B and licensing deals that defined the quarter.
